{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T19:12:30Z","timestamp":1762888350172,"version":"3.45.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.eclinm.2021.101031","type":"journal-article","created":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T01:15:34Z","timestamp":1626484534000},"page":"101031","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Association of Neo-Family History Score with pathological complete response, safety, and survival outcomes in patients with breast cancer receiving neoadjuvant platinum-based chemotherapy: An exploratory analysis of two prospective trials"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1247-7239","authenticated-orcid":false,"given":"Yaqian","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanping","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaohui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuguang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3147-0702","authenticated-orcid":false,"given":"Jinsong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9938","key":"10.1016\/j.eclinm.2021.101031_bib0001","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.eclinm.2021.101031_bib0002","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1093\/annonc\/mdt131","article-title":"Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer","volume":"24","author":"Kim","year":"2013","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.eclinm.2021.101031_bib0003","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1021\/cr980421n","article-title":"Structure, recognition, and processing of cisplatin-DNA adducts","volume":"99","author":"Jamieson","year":"1999","journal-title":"Chem Rev"},{"issue":"5","key":"10.1016\/j.eclinm.2021.101031_bib0004","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1021\/cr068207j","article-title":"Direct cellular responses to platinum-induced DNA damage","volume":"107","author":"Jung","year":"2007","journal-title":"Chem Rev"},{"issue":"7","key":"10.1016\/j.eclinm.2021.101031_bib0005","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1200\/JCO.2009.22.4725","article-title":"Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer","volume":"28","author":"Silver","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.eclinm.2021.101031_bib0006","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.ejca.2007.02.002","article-title":"A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer","volume":"43","author":"Villman","year":"2007","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.eclinm.2021.101031_bib0007","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00280-010-1401-2","article-title":"Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer","volume":"67","author":"Lu","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"10.1016\/j.eclinm.2021.101031_bib0008","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/annonc\/mdn748","article-title":"Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer","volume":"20","author":"Frasci","year":"2009","journal-title":"Ann Oncol"},{"issue":"45","key":"10.1016\/j.eclinm.2021.101031_bib0009","doi-asserted-by":"crossref","first-page":"79305","DOI":"10.18632\/oncotarget.17954","article-title":"Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase II study","volume":"8","author":"Zhou","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.eclinm.2021.101031_bib0010","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/sj.bjc.6603973","article-title":"Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy","volume":"97","author":"Wynne","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eclinm.2021.101031_bib0011","article-title":"Prevalence of homologous recombination-related gene mutations across multiple cancer types","volume":"2018","author":"Heeke","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2021.101031_bib0012","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1200\/JCO.2008.20.7019","article-title":"Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy","volume":"28","author":"Byrski","year":"2010","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.eclinm.2021.101031_bib0013","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1002\/cncr.30808","article-title":"The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer","volume":"123","author":"Pomerantz","year":"2017","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.eclinm.2021.101031_bib0014","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/annonc\/mdy460","article-title":"Survival analysis of carboplatin added to an anthracycline\/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto","volume":"29","author":"Loibl","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2021.101031_bib0015","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1023\/B:JOMG.0000048770.90334.3b","article-title":"The genetic epidemiology of breast cancer genes","volume":"9","author":"Thompson","year":"2004","journal-title":"J Mammary Gland Biol Neoplas"},{"issue":"4","key":"10.1016\/j.eclinm.2021.101031_bib0016","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.2014.57.1414","article-title":"Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer","volume":"33","author":"Couch","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2021.101031_bib0017","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.prp.2018.04.014","article-title":"Upregulation of LncRNA FEZF-AS1 is associated with advanced clinical stages and family history of cancer in patients with NSCLC","volume":"214","author":"Gong","year":"2018","journal-title":"Pathol Res Pract"},{"issue":"2","key":"10.1016\/j.eclinm.2021.101031_bib0018","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4161\/epi.26880","article-title":"Differences in DNA methylation by extent of breast cancer family history in unaffected women","volume":"9","author":"Delgado-Cruzata","year":"2014","journal-title":"Epigenetics"},{"issue":"3","key":"10.1016\/j.eclinm.2021.101031_bib0019","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00280-015-2788-6","article-title":"Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma","volume":"76","author":"Fogelman","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.eclinm.2021.101031_bib0020","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10549-017-4325-2","article-title":"Family history and risk of breast cancer: an analysis accounting for family structure","volume":"165","author":"Brewer","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"13","key":"10.1016\/j.eclinm.2021.101031_bib0021","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/jama.1993.03510130069033","article-title":"A comprehensive evaluation of family history and breast cancer risk. The utah population database","volume":"270","author":"Slattery","year":"1993","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.eclinm.2021.101031_bib0022","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/oxfordjournals.aje.a009506","article-title":"Family history score as a predictor of breast cancer mortality: prospective data from the cancer prevention study II, United States, 1982-1991","volume":"147","author":"Yang","year":"1998","journal-title":"Am J Epidemiol"},{"issue":"7","key":"10.1016\/j.eclinm.2021.101031_bib0023","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jama.2019.10987","article-title":"Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive services task force recommendation statement","volume":"322","author":"Force","year":"2019","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.eclinm.2021.101031_bib0024","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1200\/JCO.2001.19.8.2247","article-title":"Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic","volume":"19","author":"Martin","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2021.101031_bib0025","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.breast.2017.01.016","article-title":"Family history of cancer other than breast or ovarian cancer in first-degree relatives is associated with poor breast cancer prognosis","volume":"32","author":"Song","year":"2017","journal-title":"Breast"},{"issue":"8","key":"10.1016\/j.eclinm.2021.101031_bib0026","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/jnci\/djy088","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK): an abridged explanation and elaboration","volume":"110","author":"Sauerbrei","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"31","key":"10.1016\/j.eclinm.2021.101031_bib0027","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.eclinm.2021.101031_bib0028","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.2018.36.15_suppl.589","article-title":"Ki67 to predict RCB0\/I after neoadjuvant chemotherapy and endocrine therapy in HER2- breast cancer patients from ABCSG 34","volume":"36","author":"Singer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.eclinm.2021.101031_bib0029","doi-asserted-by":"crossref","first-page":"5460","DOI":"10.1158\/1078-0432.CCR-15-0384","article-title":"Identification of biomarkers including 18FDG-PET\/CT for early prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer","volume":"21","author":"Humbert","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.eclinm.2021.101031_bib0030","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1634\/theoncologist.2015-0312erratum","article-title":"High proliferation predicts pathological complete response to neoadjuvant chemotherapy in early breast cancer","volume":"21","author":"Alba","year":"2016","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.eclinm.2021.101031_bib0031","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","article-title":"Tailoring therapies\u2013improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015","volume":"26","author":"Coates","year":"2015","journal-title":"Ann Oncol"},{"issue":"9291","key":"10.1016\/j.eclinm.2021.101031_bib0032","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(01)06524-2","article-title":"Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease","volume":"358","year":"2001","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.eclinm.2021.101031_bib0033","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/(SICI)1097-0142(19961001)78:7<1417::AID-CNCR7>3.0.CO;2-H","article-title":"Family history and survival of young women with invasive breast carcinoma","volume":"78","author":"Malone","year":"1996","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2021.101031_bib0034","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources","volume":"4","author":"Huang da","year":"2009","journal-title":"Nat Protoc"},{"issue":"1","key":"10.1016\/j.eclinm.2021.101031_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/nar\/gkn923","article-title":"Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists","volume":"37","author":"Huang da","year":"2009","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"10.1016\/j.eclinm.2021.101031_bib0036","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1200\/JCO.2002.09.023","article-title":"The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2","volume":"20","author":"Lakhani","year":"2002","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.eclinm.2021.101031_bib0037","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/oxfordjournals.aje.a010265","article-title":"Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status","volume":"151","author":"Huang","year":"2000","journal-title":"Am J Epidemiol"},{"issue":"17","key":"10.1016\/j.eclinm.2021.101031_bib0038","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1038\/sj.onc.1210885","article-title":"The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1\/BRCA2-deficient and ER\/PR\/ERBB2-triple-negative breast cancer","volume":"27","author":"Tommiska","year":"2008","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.eclinm.2021.101031_bib0039","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.neo.2014.09.009","article-title":"Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts","volume":"16","author":"Abdel-Fatah","year":"2014","journal-title":"Neoplasia"},{"issue":"11","key":"10.1016\/j.eclinm.2021.101031_bib0040","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/jmg.2010.078113","article-title":"A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations","volume":"47","author":"Wilson","year":"2010","journal-title":"J Med Genet"},{"issue":"5","key":"10.1016\/j.eclinm.2021.101031_bib0041","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1001\/jamaoncol.2020.0007","article-title":"Association of Germline variant status with therapy response in high-risk early-stage breast cancer: a secondary analysis of the Geparocto randomized clinical trial","volume":"6","author":"Pohl-Rescigno","year":"2020","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2021.101031_bib0042","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","article-title":"Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial","volume":"24","author":"Tutt","year":"2018","journal-title":"Nat Med"},{"issue":"34","key":"10.1016\/j.eclinm.2021.101031_bib0043","doi-asserted-by":"crossref","first-page":"56626","DOI":"10.18632\/oncotarget.17993","article-title":"Predictive factors of pathologic complete response in HER2-positive and axillary lymph node positive breast cancer after neoadjuvant paclitaxel, carboplatin plus with trastuzumab","volume":"8","author":"Ding","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.eclinm.2021.101031_bib0044","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/jamaoncol.2017.1007","article-title":"Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the geparsixto randomized clinical trial","volume":"3","author":"Hahnen","year":"2017","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.eclinm.2021.101031_bib0045","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1038\/bjc.1998.374","article-title":"Family history and survival in premenopausal breast cancer","volume":"77","author":"Mohammed","year":"1998","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.eclinm.2021.101031_bib0046","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/bjs.9816","article-title":"Family history and outcome of young patients with breast cancer in the UK (POSH study)","volume":"102","author":"Eccles","year":"2015","journal-title":"Br J Surg"},{"issue":"1 Pt 1","key":"10.1016\/j.eclinm.2021.101031_bib0047","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1158\/1078-0432.CCR-1025-3","article-title":"Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays","volume":"10","author":"Kang","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.eclinm.2021.101031_bib0048","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s12032-014-0352-6","article-title":"Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10\/STAT3\/bcl-2 signaling pathway","volume":"32","author":"Yang","year":"2015","journal-title":"Med Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2021.101031_bib0049","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ygyno.2019.04.009","article-title":"Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?","volume":"154","author":"Tomao","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2021.101031_bib0050","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1159\/000354834","article-title":"The influence of BRCA1\/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients","volume":"85","author":"Huszno","year":"2013","journal-title":"Oncology"},{"key":"10.1016\/j.eclinm.2021.101031_bib0051","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejca.2020.12.007","article-title":"Germline BRCA1\/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy","volume":"145","author":"Furlanetto","year":"2021","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.eclinm.2021.101031_bib0052","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1213\/01.ane.0000204318.35194.ed","article-title":"Dysregulation of cellular calcium homeostasis in chemotherapy-evoked painful peripheral neuropathy","volume":"102","author":"Siau","year":"2006","journal-title":"Anesth Analg"},{"issue":"5","key":"10.1016\/j.eclinm.2021.101031_bib0053","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.clinthera.2019.04.003","article-title":"Computational drug discovery in chemotherapy-induced alopecia via text mining and biomedical databases","volume":"41","author":"Zhang","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.eclinm.2021.101031_bib57","series-title":"The Mathematics of Heredity","first-page":"23","author":"Mal\u00e9cot","year":"1969"},{"issue":"7","key":"10.1016\/j.eclinm.2021.101031_bib58","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jama.2019.10987","article-title":"Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement","volume":"322","author":"U. S. Preventive Services Task Force","year":"2019","journal-title":"JAMA"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537021003114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537021003114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T19:08:39Z","timestamp":1762888119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537021003114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":55,"alternative-id":["S2589537021003114"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2021.101031","relation":{},"ISSN":["2589-5370"],"issn-type":[{"type":"print","value":"2589-5370"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Neo-Family History Score with pathological complete response, safety, and survival outcomes in patients with breast cancer receiving neoadjuvant platinum-based chemotherapy: An exploratory analysis of two prospective trials","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2021.101031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101031"}}